BioNTech SE
(NASDAQ : BNTX)

( )
BNTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.94%245.371.5%$940.74m
MRNAModerna, Inc. 0.71%144.270.0%$849.73m
REGNRegeneron Pharmaceuticals, Inc. 0.84%612.492.6%$526.18m
VRTXVertex Pharmaceuticals, Inc. 3.19%292.551.9%$516.29m
GILDGilead Sciences, Inc. 0.80%63.081.0%$513.27m
NVAXNovavax, Inc. -0.27%51.6775.7%$422.21m
ILMNIllumina, Inc. 0.20%193.933.3%$361.41m
BIIBBiogen, Inc. 0.26%211.931.8%$242.32m
SNSSSunesis Pharmaceuticals, Inc. 9.63%2.960.7%$206.91m
CRSPCRISPR Therapeutics AG 2.78%66.960.6%$173.29m
BNTXBioNTech SE 1.32%134.040.0%$153.17m
BMRNBioMarin Pharmaceutical, Inc. 2.72%86.854.2%$121.28m
EXASEXACT Sciences Corp. 6.89%45.1517.7%$107.32m
IOVAIovance Biotherapeutics, Inc. 0.19%10.350.0%$103.94m
TECHBio-Techne Corp. 2.16%352.764.5%$95.22m

Company Profile

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.